Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 2Peritoneal Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Hyperthermic Intraperitoneal Chemotherapy 28Paclitaxel 24Cisplatin 23Oxaliplatin 18Cytoreduction Surgical Procedures 17Carboplatin 17Fluorouracil 14Bevacizumab 10Mitomycin 9Leucovorin 9Doxorubicin 9Docetaxel 6Gemcitabine 5130-nm albumin-bound paclitaxel 5Surgical Procedures, Operative 4Neoadjuvant Therapy 4Laparoscopy 4Blood Specimen Collection 4Albumin-Bound Paclitaxel 4sodium thiosulfate 3liposomal doxorubicin 3catumaxomab 3Taxes 3Drug Therapy 3Chemotherapy, Adjuvant 3tremelimumab 2relacorilant 2pembrolizumab 2olaparib 2nintedanib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peritoneal Neoplasms × vandetanib × Gynecologic × Clear all
NCT00445549 2012-06-26

Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
12 enrolled 5 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡